[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,007,188
  • Shares Outstanding, K 641,521
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -35 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.61
  • Price/Sales 5.69
  • Price/Cash Flow N/A
  • Price/Book 3.75

Options Overview Details

View History
  • Implied Volatility 99.80% (+10.17%)
  • Historical Volatility 76.36%
  • IV Percentile 24%
  • IV Rank 7.53%
  • IV High 429.98% on 10/10/25
  • IV Low 72.92% on 03/20/26
  • Expected Move (DTE 14) 0.1700 (10.83%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 561
  • Volume Avg (30-Day) 1,042
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 66,090
  • Open Int (30-Day) 59,510
  • Expected Range 1.4000 to 1.7400

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 4
  • High Estimate $0.00
  • Low Estimate $-0.02
  • Prior Year $-0.03
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +28.69%
on 07/31/26
1.6300 -3.68%
on 08/05/26
+0.1300 (+9.03%)
since 07/06/26
3-Month
1.0800 +45.37%
on 06/11/26
1.6300 -3.68%
on 08/05/26
-0.0100 (-0.63%)
since 05/06/26
52-Week
1.0400 +50.96%
on 11/07/25
2.0100 -21.89%
on 02/19/26
+0.1800 (+12.95%)
since 08/06/25

Most Recent Stories

More News
Geron: Q2 Earnings Snapshot

Geron: Q2 Earnings Snapshot

GERN : 1.5700 (-3.68%)
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses...

GERN : 1.5700 (-3.68%)
Geron's Estimate Revisions Suggest Analysts Are Adjusting to Something

Barchart Research What to Expect from GERN Earnings GERN Generated August 4, 2026 Current Price $1.3400 EPS Estimate $$-0.01 Consensus Rating Moderate Buy Average Move 8.91% Geron's Estimate Revisions...

GERN : 1.5700 (-3.68%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options...

GERN : 1.5700 (-3.68%)
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5700 (-3.68%)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.5700 (-3.68%)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5700 (-3.68%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options...

GERN : 1.5700 (-3.68%)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5700 (-3.68%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1221 (+1.67%)
BIOA : 11.27 (+2.64%)
LCTX : 1.1300 (-0.88%)
GERN : 1.5700 (-3.68%)
FATE : 2.49 (-4.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.7067
2nd Resistance Point 1.6633
1st Resistance Point 1.6167
Last Price 1.5700
1st Support Level 1.5267
2nd Support Level 1.4833
3rd Support Level 1.4367

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Last Price 1.5700
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.